CEO at Spyre Therapeutics, Inc. Sells $1.38 million in Stock

Cameron Turtle, who serves as CEO at Spyre Therapeutics, Inc. (SYRE), sold 15,000 shares of the company's stock, according to a disclosure filed with the U.S. Securities and Exchange Commission.

The transaction was executed at a price of $92.01 per share, for a total value of approximately $1.38 million.

Insider transactions of this kind are publicly disclosed through Form 4 filings with the SEC, which must generally be submitted within two business days of the trade date.

Insider sales are common and can occur for reasons unrelated to a company's outlook, including scheduled trading plans, diversification, or personal financial planning.